ABBV · AbbVie Inc.
Is ABBV setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on AbbVie Inc., in one place.
Today's breakout radarIs ABBV setting up for a breakout?
Breakout Radar API →ABBV reports earnings on Oct 30, 2026 — a breakout right before a report can reverse on the numbers.
Not today. ABBV is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about ABBV?
Stock Sentiment API →Bulls: AbbVie has raised its quarterly dividend from $0.40 at its first payment in January 2013 to $1.73 this month — a 332.50% increase in under 14 years. The company filed a BLA with the FDA for etentamig after the positive Phase 3 CERVINO study in multiple myeloma, citing an overall response rate of 74.0% vs. 45.7% for standard therapies and a 60% reduction in risk of disease progression or death. A trader's technical setup on the $ABBV Nov 295 call cites a $284.78–$288.80 zone, invalidation on a close under $282.30, and objectives of $291.40 then $300 — about 1.6% and 4.6% upside against 1.6% risk, better than 2-to-1 to the second target; another post flags a break of 291 then 300.
Bears: One critic argues the $11B acquisition behind the drug will push insurance premiums higher, saying the product offers no advantage over a generic standard of care beyond a slight reduction in the number of tiny, often painless, injections per year.
Reading from Oct 27, 2026; each post classified by AI, weighted by engagement.
What is the news saying about ABBV?
News Sentiment API →No recent news reading for ABBV. The News Sentiment API reads today's headlines on any US stock.
Are ABBV insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Donoghoe Nicholas$8.2M · Aug 14, 2026
- Sold · Purdue David Ryan$1.2M · Mar 4, 2026
- Sold · Siatis Perry C$612K · Mar 2, 2026
- Sold · Siatis Perry C$2.4M · Mar 2, 2026
- Sold · Siatis Perry C$1.3M · Mar 2, 2026
How is AbbVie Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $17.0B | +10% | $3.6B | $2.03 |
| Mar 31, 2026 | $15.0B | +12% | $695.0M | $0.39 |
| Sep 30, 2025 | $15.8B | +9% | $186.0M | $0.10 |
| Jun 30, 2025 | $15.4B | +7% | $938.0M | $0.52 |
From the company's SEC filings (10-Q and 10-K).
What does AbbVie Inc. expect?
Company Guidance API →- 2026 full-year · adjusted diluted eps · 8-K filed Sep 3, 2026
“AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07”
- 2026 third-quarter · adjusted diluted eps · 8-K filed Sep 3, 2026
“reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88”
- Full-Year 2026 · adjusted diluted eps · 8-K filed Jul 31, 2026
“AbbVie is updating its adjusted diluted EPS guidance range for the full year 2026 from $13.91 - $14.11 to $13.87 - $14.07, reflecting a change of $0.04 at the midpoint.”
- beginning in 2032 · adjusted diluted earnings per share (eps) accretion · 8-K filed Jun 22, 2026
“The proposed transaction is expected to be accretive to AbbVie s adjusted diluted earnings per share (EPS) beginning in 2032.”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.